BridgeBio Pharma to Participate in September Investor Events
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
- S&P 500, Dow futures muted after big bank earnings, chip slide weighs
- Oil prices ease as traders monitor Russian diesel deal, Saudi attacks
- JPMorgan shares edge lower after third-quarter FICC revenue miss
- Fed’s Waller says US bond yield rise driven by growth, not inflation
- Wells Fargo beats profit estimates despite revenue miss
- Bausch + Lomb names Appio interim CEO as Saunders departs
- Cerebras Systems hits new 52-week low on unlock concerns
- Getty Images to go private via prepackaged Chapter 11 restructuring
- Sysco calls on Teamsters to end LA strike after economic deal reached
- Kroger (KR) To Cut Corporate Workforce By About 3,000 Over 3 Years - Bloomberg
Ainylam Pharmaceuticals shares tumble following study results, BridgeBio Pharma rises
August 30, 2024 7:39 AM EDTAlnylam Pharma (NASDAQ: ALNY) shares tumbled 11.5% Friday following the release of results from its HELIOS-B Phase 3 study of vutrisiran, despite the study meeting all primary and secondary endpoints.
The investigational RNAi therapeutic, aimed at treating ATTR amyloidosis with cardiomyopathy (ATTR-CM), was shown to reduce the risk of death and cardiovascular events by 28% compared to placebo in the overall... More



